Exploring Scholar Rock Holding Corporation (SRRK) Investor Profile: Who’s Buying and Why?

You've been watching Scholar Rock Holding Corporation (SRRK) and asking the right question: why is this stock moving so sharply, and who is defintely buying it? The answer is complex, but the money trail is clear. As of November 2025, institutional interest is exceptionally high, with institutional ownership sitting at nearly 116%, meaning the total shares held by major funds actually exceeds the float due to short interest and other factors. Firms like Fmr Llc, holding around 14.0 million shares, and BlackRock, Inc., with roughly 6.76 million shares, are among the top holders, signaling conviction in the long-term pipeline, specifically the Spinal Muscular Atrophy (SMA) treatment, apitegromab. This institutional accumulation persists even after the Q3 2025 earnings call, which saw the company's stock surge over 22% on news of a constructive FDA meeting, despite reporting an Earnings Per Share (EPS) of -$0.90, missing the consensus forecast. With the company reporting a cash balance of $369.6 million at the end of Q3 2025, the institutional money is betting that the path to a potential $5 billion annual SMA market is worth the near-term regulatory risk. So, are these funds seeing a clear runway to commercialization, or is this a classic biotech gamble on a single asset?

Who Invests in Scholar Rock Holding Corporation (SRRK) and Why?

You're looking at Scholar Rock Holding Corporation (SRRK), a clinical-stage biotech, and trying to figure out whose money is driving the stock. The direct takeaway is that this is overwhelmingly an institutional-driven stock, where specialized biotech funds and massive asset managers are making a high-conviction, long-term bet on the success of their lead drug, apitegromab.

As of late 2025, a staggering amount of the company is held by institutions. Specifically, 536 funds or institutions report holding positions, collectively owning about 129.4 million shares. That's a huge number for a company with a market capitalization of roughly $3.83 billion as of October 2025. This high institutional ownership, which is over 120% of the shares outstanding (due to how different reporting mechanisms count shares), means retail investors are essentially riding the coattails of these major players.

Key Investor Types: The Institutional Powerhouse

The investor base for Scholar Rock Holding Corporation is a mix of three main groups, but institutional money is the dominant force. The retail investor (you and me) holds the remaining float alongside company insiders, who own about 3.69% of the shares.

The institutional cohort breaks down into a few critical sub-groups:

• Mega-Asset Managers: These are the giants of passive and active investing. Firms like BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp hold shares primarily for their index funds and large mutual funds. BlackRock, Inc. alone held over 6.76 million shares as of the end of Q3 2025.
• Specialized Biotech/Hedge Funds: These investors are the most active and have the deepest understanding of the clinical pipeline. They include firms like Siren, L.L.C. (holding 9.25 million shares), Samsara Biocapital, Llc (5.61 million shares), and Redmile Group, Llc. They are making a high-risk, high-reward bet on the clinical trial outcomes.
• Growth-Focused Mutual Funds: Funds from T. Rowe Price Group, Inc. (holding 6.88 million shares) and Fmr Llc (the largest holder with over 14.01 million shares) are active managers betting on the company's long-term growth trajectory.

Investment Motivations: Betting on a $5 Billion Market

Investors are buying Scholar Rock Holding Corporation stock for one simple reason: the massive, near-term growth opportunity in its lead product, apitegromab. The company is not a value play; it's a pure growth story in the biotechnology space. Here's the quick math on the motivation:

• SMA Market Potential: The Spinal Muscular Atrophy (SMA) treatment market is estimated to be worth around $5 billion annually. Scholar Rock Holding Corporation is positioning apitegromab as the world's first muscle-targeted therapy for SMA, which gives it a unique selling point against existing gene therapies and antisense oligonucleotides.
• Pipeline Validation: The company is moving toward an FDA resubmission for apitegromab, with a potential U.S. launch expected in 2026. This regulatory catalyst is the main driver of the stock's volatility and upside.
• Strong Cash Runway: Despite a net loss of $102.2 million in Q3 2025, the company ended the quarter with a cash position of $369.6 million. This is defintely a key factor, as it's expected to fund operations into 2027, alleviating near-term financing risk.

The consensus price target from analysts, averaging around $43.69 to $47.73 as of November 2025, implies a significant upside from the current trading price, which fuels the conviction of these institutional buyers.

Investment Strategies: Growth, Event-Driven, and Long-Term

The nature of Scholar Rock Holding Corporation's business-a clinical-stage biotech-dictates the strategies employed by its investors. You won't see dividend-focused or deep-value strategies here, since the company is currently reporting a nine-month net loss of $286.97 million and projected annual revenue of only $76 million for 2025.

The primary strategies are:

• Long-Term Growth Holding: This is the dominant strategy for the largest holders like Fmr Llc and BlackRock, Inc. They are holding through the volatility, betting on the successful commercialization of apitegromab and the rest of the pipeline, which includes plans to initiate clinical development in a second neuromuscular disorder by the end of 2025.
• Event-Driven Trading: Specialized hedge funds and some active traders engage in event-driven strategies, buying or selling based on key clinical and regulatory milestones. For example, the stock's surge after the Q3 2025 earnings call, despite an EPS miss of -$0.90, was a reaction to positive updates on the FDA meeting for apitegromab.
• Venture-Style Investing (Public Equities): Funds like Samsara BioCapital, Llc, which specialize in life sciences, treat their public investment like a late-stage venture capital round. They are in for the long haul, focusing on the science and the ultimate market penetration.

The high put/call ratio of 1.12 on the stock, however, suggests that some investors are also using options to hedge their positions or are betting on a short-term pullback, reflecting the inherent regulatory risk in the biotech sector. If you want to understand the foundational belief behind these bets, you should review the Mission Statement, Vision, & Core Values of Scholar Rock Holding Corporation (SRRK).

Institutional Ownership and Major Shareholders of Scholar Rock Holding Corporation (SRRK)

The short answer is that Scholar Rock Holding Corporation (SRRK) is a high-conviction institutional bet, not a retail favorite. With institutional investors owning a massive 91.08% of the company's stock, the buying is a clear signal that the smart money is placing a large wager on the success of their clinical pipeline, particularly the Phase 3 asset, Apitegromab.

As a seasoned financial analyst, I see this level of concentration as a double-edged sword: it provides a strong, stable base of capital but also means the stock's performance is deeply tied to the success of a few key drug trials. This isn't a slow-burn value play; it's a biotech growth story. For a deeper dive into the company's foundation, you can check out Scholar Rock Holding Corporation (SRRK): History, Ownership, Mission, How It Works & Makes Money.

Top Institutional Investors: Who's Buying In

The institutional roster for Scholar Rock Holding Corporation is exactly what you'd expect for a clinical-stage biotech: a mix of large index funds and specialist healthcare-focused hedge funds. As of the most recent filings (Q3 2025), a total of 536 funds or institutions reported positions, holding a combined 129,396,000 shares.

The largest holders include some of the biggest names in asset management, which is defintely a vote of confidence in the long-term potential of their proprietary technology platform. Here's a look at the top institutional holders and their share counts from the Q3 2025 reporting period:

Recent Changes in Ownership: The Accumulation Trend

The general trend is one of accumulation, which is a key signal for a growth stock. Total shares owned by institutions increased by a solid 5.60% in the three months leading up to the end of Q3 2025. Plus, the number of institutional owners grew by 7.63%, adding 38 new funds to the shareholder list. This suggests broadening interest, not just deeper conviction from existing holders.

But, you need to look at the individual moves, too. For example, Wellington Management Group Llp was a massive buyer, boosting its position by 124.5% in the third quarter, acquiring an additional 2,521,022 shares. That's a huge bet. On the flip side, Price T Rowe Associates Inc /md/ decreased its stake by 27.29%, showing that not everyone is uniformly bullish on the near-term outlook. This is normal in biotech; portfolio managers rotate based on clinical trial milestones.

• Wellington Management Group LLP: Increased position by 124.5%.
• Vanguard Group Inc.: Grew position by 1.1%.
• Price T Rowe Associates: Decreased stake by 27.29%.

Impact of Institutional Investors on Strategy and Price

The high institutional ownership-over 9 out of every 10 shares-means these large investors essentially control the stock's volatility and strategic direction. Their focus is clearly on the high-potential pipeline assets, specifically Apitegromab, which is in a Phase 3 clinical trial for Spinal Muscular Atrophy (SMA), and SRK-181 for cancer.

Here's the quick math: the total institutional value of long positions is over $4.5 billion. This capital is a direct vote on the probability of Apitegromab's success and the future commercial potential of the drug. The institutional concentration helps stabilize the stock price against minor market noise, but it also means any major clinical trial readout will cause an explosive move. Analysts are already factoring this in, with the average one-year price target sitting at $48.86/share as of November 2025, representing a potential upside of nearly 34% from recent closing prices. Institutional buying is the engine driving that price expectation.

Key Investors and Their Impact on Scholar Rock Holding Corporation (SRRK)

You're looking at Scholar Rock Holding Corporation (SRRK) and trying to figure out who is driving the bus, and honestly, the answer is a mix of biotech specialists and massive index players. The institutional ownership is high, which tells you that big money sees a long-term play here, despite the near-term volatility. As of the third quarter of 2025, over 535 institutional owners held a total of approximately 129.4 million shares, showing a strong conviction from professional money managers.

The investor profile is split between large, passive funds-the behemoths of the financial world-and specialized, often more active, biotech venture capital firms. This blend creates a dynamic where the stock gets both foundational stability and sharp, event-driven movement. Your decision needs to weigh the long-term clinical story against the short-term trading patterns of these key players.

The Foundational Giants: BlackRock, Vanguard, and FMR LLC

The largest shareholders are the household names, the ones whose sheer size dictates a baseline for the stock. These firms are generally passive, meaning they aren't pushing for a new CEO or a change in strategy; they hold the stock because it's in an index or a growth-focused fund. FMR LLC, the parent company of Fidelity, is the largest institutional holder, with approximately 14.4 million shares as of June 2025.

BlackRock, Inc. and The Vanguard Group, Inc. are also top-tier holders. BlackRock, Inc. held roughly 6.76 million shares as of September 30, 2025, and Vanguard Group Inc. held about 4.91 million shares. Their impact is less about direct influence on management and more about liquidity and stability. When BlackRock, Inc. increases its position by a small percentage, like the 0.96% increase reported in Q3 2025, it signals a quiet, steady confidence in the long-term growth trajectory. This is a defintely a good sign for stability.

• FMR LLC: Largest holder, provides foundational stability.
• BlackRock, Inc.: Q3 2025 holding was 6.76 million shares.
• Vanguard Group Inc.: Q3 2025 holding was about 4.91 million shares.

Specialized Funds: The Biotech Drivers and Their Recent Moves

The real action and near-term stock movement often come from the specialized funds, particularly those focused on the biotechnology sector. These investors are experts in clinical trials and regulatory timelines, and their buying or selling can be a powerful signal about the perceived success of drugs like apitegromab for Spinal Muscular Atrophy (SMA). Samsara BioCapital LLC, a major biotech-focused investor, held approximately 5.61 million shares, representing a significant 5.84% ownership as of November 2025. Redmile Group LLC is another key player, holding around 3.9 million shares.

You need to pay close attention to the quarterly changes here. For example, in the third quarter of 2025, Wellington Management Group LLP made a massive move, increasing their stake by an incredible 124.503%, bringing their total to about 4.55 million shares. That's a huge vote of confidence, likely tied to the progress of the apitegromab Biologics License Application (BLA) resubmission, which is anticipated in 2026. Conversely, Price T Rowe Associates Inc. MD decreased their position by 21.441% in the same quarter, suggesting a rotation out of the stock, perhaps due to the Q3 2025 net loss of $102.2 million.

Here's the quick math on the conviction of the specialized funds:

Investor Influence and the Path Ahead

The influence of these investors is two-fold. The large, passive holders ensure a liquid market, which is crucial for a biotech stock with a market capitalization of around $3.59 billion. The specialized funds, however, are the ones who truly signal the market's belief in the drug pipeline. Their significant capital commitment-like the $369.6 million in cash and equivalents Scholar Rock Holding Corporation (SRRK) had as of September 30, 2025, which is expected to fund operations into 2027-is a direct endorsement of the company's strategy.

When a biotech specialist like Samsara BioCapital LLC maintains a steady, large position, they are betting on the successful commercialization of the lead product. You can read more about the core strategy in the Mission Statement, Vision, & Core Values of Scholar Rock Holding Corporation (SRRK). The high institutional ownership, which is over 100% of the float in some reports, suggests that conviction is very strong among professional investors. The current share price of $30.07 as of November 13, 2025, reflects this high interest, but it also means the stock is highly sensitive to clinical news. Finance: Monitor the next 13F filings for any further large stake changes by Wellington Management Group LLP or Redmile Group LLC to gauge sentiment on the Q4 2025 IND clearance of SRK-439.

Market Impact and Investor Sentiment

You want to know who is buying Scholar Rock Holding Corporation (SRRK) and why, especially with the recent volatility. The direct takeaway is that institutional conviction remains high, despite the company's clinical-stage financial profile, with major funds increasing their stakes in Q3 2025, signaling a belief in the long-term commercial potential of apitegromab.

Investor sentiment is a complex blend of bullish long-term institutional accumulation and cautious short-term options trading. While the total number of shares owned by institutions increased by 5.60% in the last three months of 2025, the options market's put/call ratio of 1.12 suggests a slightly bearish outlook, meaning more put options (bets the stock will fall) are open than calls (bets it will rise). It's a classic biotech split: smart money is accumulating, but traders are hedging their near-term bets.

• Institutional ownership sits at over 91% of the stock.
• Retail sentiment spiked to 'extremely bullish' in November 2025.
• The big money is still buying the story.

The Institutional Accumulation Story

The investor profile for Scholar Rock Holding Corporation is dominated by large, sophisticated institutional players like BlackRock, Inc., Vanguard Group Inc, and specialist biotech funds. These firms hold a staggering amount of the company's stock, with institutional ownership nearing 120.59% of the shares outstanding, which is common in heavily-weighted, low-float biotech stocks. The Q3 2025 13F filings show clear accumulation, particularly from a few key names.

Wellington Management Group Llp, for instance, made a massive move, increasing its position by 124.503% in the third quarter of 2025, adding over 2.5 million shares to hold a total of 4,545,887 shares valued at approximately $180.4 million. Conversely, Price T Rowe Associates decreased its position by 21.441%, selling nearly 1.9 million shares, showing that not all large holders are in lockstep. This divergence shows active management is at play, not just passive indexing.

Here's a snapshot of the top institutional holders as of the most recent Q3 2025 filings:

Market Reactions and Insider Confidence

The stock market has reacted sharply to both good news and financial misses, which is typical for a late-stage biopharmaceutical company. When Scholar Rock Holding Corporation reported a net loss per share of ($0.90) for Q3 2025, missing analyst consensus, the stock still surged over 25% on November 14, 2025. Why? Because the market prioritized the news about the new manufacturing facility and the planned 2026 resubmission for apitegromab, their lead product candidate for spinal muscular atrophy (SMA). That's a clear signal that the market is focused on the regulatory and commercial timeline, not just the burn rate.

Insider activity also provides a strong signal. Director Srinivas Akkaraju made a significant open market purchase of 500,439 shares on October 2, 2025, for a total of $18,807,352.19. This kind of large, direct purchase from a director is a powerful vote of confidence, especially in the wake of the Q3 earnings loss. It tells you the people who know the company best are putting their own capital on the line for the commercial future. For a deeper dive into the company's background and ownership structure, you can check out Scholar Rock Holding Corporation (SRRK): History, Ownership, Mission, How It Works & Makes Money.

Analyst Perspectives on Key Investors' Impact

Analyst consensus is overwhelmingly positive, which is defintely influenced by the quality and size of the key institutional investors. The average one-year price target from analysts as of mid-November 2025 is around $48.86 per share, suggesting an upside of about 33.97% from a recent closing price of $36.47. Firms like JP Morgan and Wolfe Research have recently maintained or initiated 'Overweight' or 'Strong Buy' ratings, reflecting optimism.

Here's the quick math: The analysts are essentially valuing the company based on the probability of a successful launch for apitegromab. When a firm like Wellington Management Group Llp dramatically increases its stake, it validates the long-term model and gives analysts more confidence in their price targets. The analysts are betting that the projected annual revenue of $76 million (MM) for the near term, and the eventual non-GAAP EPS of ($2.36), will quickly pivot once apitegromab hits the market. The big investors are buying into that same commercialization narrative.

Next step: Check the Q4 2025 earnings call transcript for any forward guidance on the apitegromab regulatory filing timeline; that will be the next major catalyst to move the stock.